Summary of clinical results

AVENE
ROSAMED SPF50+ Concentré hydratant protecteur

Effectiveness of ROSAMED SPF50+ Protective Moisturizing Concentrate

Tolerance and efficacy in monotherapy of ROSAMED SPF50+ Protective Moisturizing Concentrate in adults with mild to moderate erythematotelangiectatic rosacea, under dermatological and ophthalmological control.

Population

36 women aged 33 to 65 with mild to moderate erythematote-langiectatic rosacea .

 

Application of ROSAMED Protective Moisturizing Concentrate

2 applications daily (morning and early afternoon), on face and neck. 

 

Evaluation criteria

Scoring by dermatologist:

  • Physical signs: erythema (5-point scale) ; 
  • Overall evolution of rosacea (6-point scale).

Scoring by the subject :

  • Functional signs: sensations of discomfort, heat, tightness (NRS 11-point scale);
  • Frequency of flushing (5-point scale);
  • Severity of flushing (GFSS scale).

Results

After 2 weeks of twice-daily application: 

  • Improvement of rosacea in 91% of subjects;
  • Highly significant 37% reduction in erythema;
  • Highly significant reduction in sensations of discomfort (-66%), heat (-81%) and tightness (-68%);
  • Highly significant reduction in burning sensations by -96%*
graph rosamed
  • Highly significant reduction in the frequency of redness (flushing) of 49%. (p value < 0.0001).

 

Conclusion

ROSAMED SPF50+ Protective Moisturizing Concentrate, applied twice-daily, demonstrated its efficacy on the frequency of redness (flushing) and on the physical and functional signs of rosacea, as early as 15 days later.